Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
LL,
The last TD report put a value of 3.79p per share on Covidity.
Remember this is "risk adjusted" with 10% chance of success. So if it is successful that represents 37.9p per share.
It is also a "net present value" based on sales materialising in 2023. So if it comes earlier, possibly a tad higher - 45p.
TD based their estimate on $1B sales and a 15% royalty.
And how do you put a timeline on this?
'AvidiMabTM technology to increase the avidity of human antibodies by promoting noncovalent Fc-Fc interactions. This modification also causes direct killing of cancer cells by the glycan targeting
antibodies, and therefore it is considered that this technology has the ability to create superior candidates with
increased molecular ‘stickiness’ and thereby imply reduced side-effects due to lower dosing for cancer
immunotherapy'
'The peer-reviewed paper has resulted in a number of enquiries from international bodies and larger
developers considering licencing opportunities for application with their own antibodies.'
Or indeed what may yet come from TCR's.... etc etc....
LL yes quite but what you are looking at there is expected clinical news timelines.... which of course is fair enough you can indeed go off those but I'm being more speculative in that scancell are also in many talks around many pieces of their platform... most notably of course at the moment being Covidity... and it is little possibilities like these that mean we could hear something exciting before any clinical progress...
'Richard Hatchett, CEO of CEPI. Hatchett told us the group will later this week launch the strategy for its next set of goals '
could that include Covidity for instance? possibly maybe not who knows!.... but like I say scancell are in constant talks and are actively seeking partners again that is on all parts of the pipeline...
'The Company is actively seeking development partners and additional funding (including non-dilutive funding from governments and global institutions) to support the rapid development of this vaccine.'
but yes if no news of that nature is coming then newsflow can be more expected to be driven by the progress of techs into the clinic...
I'm not going to set an upper limit on the valuation for all product lines until efficacy data is published. My very non-scientific back of the envelope calc for being 1st to market for covidity/universal covid alone is £3.4 based on their current valuation and multiplied by the first mover effect.
Afternoon LL
It will be interesting as to whether Trinity will assign any value to Covidity. I believe thy haven't up till now.
The same is true for Avidimab and the Glycans mAbs. Potentially both of these developments could separately be worth a fortune.
It's so difficult to value a company like Scancell.
Maybe they will come back with a £8 valuation :-)
I was looking at the news slide (think it is number 19). All the earliest dates are H1 2021, which I take to mean April-June, because March would be Q1 for most companies reporting their short and medium term expected news.
I am looking forward to seeing an update on Trinity Delta's share price value - for me that is the most reliable info to hand.
If/When news on Covidity is announced, I do hope it is in the region of the 2000% gains made by others, but that will probably only happen if Scancell is first to market.
On a separate note, my local medical centre has mentioned that there has been a noticeable drop in the numbers of the usual winter ailments. They plan to incorporate some of the covid practices into their normal procedures to help that continue.
Of course, exciting news could come at any time not just from Covidity but yes that is the most likely cuz well pandemic...
'The Company is actively seeking development partners and additional funding (including non-dilutive funding from governments and global institutions) to support the rapid development of this vaccine'
Cliff may have sounded like nothing much on funding /partnering will come till ph1 although he did say 'sooner than later' in his Vox presentation but I think it is obvious talks are ongoing with many interested parties,CEPI for possible instance... but not just them... and scancell and the notts team have to forge ahead to ph1 no matter what but a move in can come at any time.... if it is CEPI for instance that could impact where the trial is ran etc.... we will see :)